A phase III, randomized, multi-center, double-blind, parallel-group, placebo-controlled safety and efficacy study of SPD503 [Intuniv; guanfacine] in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).

Trial Profile

A phase III, randomized, multi-center, double-blind, parallel-group, placebo-controlled safety and efficacy study of SPD503 [Intuniv; guanfacine] in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 29 Jul 2018 Results of post hoc analysis of four studies (SPD503-301, SPD503-304, SPD503-312 and SPD503-316) published in the European Neuropsychopharmacology
    • 07 May 2008 Results of a pooled analysis presented at APS 2008, according to a Shire media release.
    • 30 Jan 2008 Results have been published (1101050)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top